Skip to main content
Interview

First-Line Brentuximab Vedotin Plus Chemotherapy Improves OS in Classical Hodgkin Lymphoma


Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses results from the ECHELON-1 trial, which found that brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) treatment resulted in a statistically significant reduction in the risk of death compared to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), with a manageable safety profile, among patients with stage III/IV classical Hodgkin lymphoma.

This interview was conducted at the 2022 ASCO Annual Meeting.